– USA, WA – Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company today announced the elections of Joe Edelman, John Fluke, and Grant Pickering to its Board as Independent Directors.
“We appreciate the strong support of our shareholders throughout this process. We are grateful that our shareholders recognize the value, contributions and expertise of Joe, John and Grant at such a pivotal time for our company. We look forward to continuing to do what we do best: successfully executing on our strategy for the benefit of all our stakeholders, especially patients and caregivers,” said CEO, Mark Litton. “
About Athira Pharma, Inc.
Athira Pharma Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline therapeutic candidates, targeting the HGF/MET neurotrophic system, for Alzheimer’s and Parkinson’s disease dementia, Dementia with Lewy bodies, and neuropsychiatric indications.
For more information: https://www.athira.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.